Glyxambi (Linagliptin, Empagliflozin)

Glyxambi is indicated as an adjunct to diet and exercise for improving glycemic control in adults with type 2 diabetes.

• Used when metformin alone does not achieve target HbA1c.
• Suitable for patients who benefit from both incretin‑based and renal glucose‑excretion mechanisms.
• Can be considered in combination with other oral antidiabetic agents, except other DPP‑4 or SGLT2 inhibitors.
• May be prescribed for individuals with established cardiovascular risk, as empagliflozin has demonstrated cardiovascular benefit.
• Provides a once‑daily dosing option to simplify therapy.

The safety profile of Glyxambi includes a range of reported adverse events, which are categorized by frequency and severity.

Common

• Upper respiratory tract infection symptoms such as nasopharyngitis.
• Genitourinary infections, including yeast infections and urinary tract infections.
• Increased urination (polyuria) and thirst (polydipsia).
• Mild gastrointestinal upset, such as nausea or abdominal discomfort.
• Headache or dizziness.

Serious

• Dehydration or hypotension, especially in patients with renal impairment.
• Ketoacidosis (euglycemic diabetic ketoacidosis).
• Severe hypersensitivity reactions, including angioedema or Stevens‑Johnson syndrome.
• Acute kidney injury.
• Significant reductions in blood pressure leading to fainting.

When prescribing Glyxambi, clinicians should evaluate several clinical factors and monitor patients for specific conditions.

• Assess renal function before initiation and periodically thereafter.
• Use caution in patients with a history of urinary or genital infections.
• Monitor for signs of volume depletion, especially in the elderly or those on diuretics.
• Evaluate cardiovascular status, as empagliflozin may lower blood pressure.
• Avoid use in patients with type 1 diabetes or diabetic ketoacidosis.
• Consider pregnancy and lactation status; safety data are limited.
• Review concomitant medications that affect glucose homeostasis.

Glyxambi may interact with other medicines, influencing its efficacy or safety. Interactions are grouped by recommended approach.

Avoid

• Concurrent use with other SGLT2 inhibitors or DPP‑4 inhibitors.
• Strong diuretics that may exacerbate dehydration or hypotension.
• Medications that cause significant renal impairment, such as NSAIDs at high dose.
• Loop diuretics combined with low fluid intake, increasing risk of renal dysfunction.

Use with caution

• Insulin or insulin secretagogues (e.g., sulfonylureas) due to increased hypoglycemia risk.
• Antihypertensive agents, especially ACE inhibitors or ARBs, because of additive blood pressure lowering.
• Rifampin or other potent enzyme inducers that may reduce empagliflozin exposure.
• Glucagon‑like peptide‑1 (GLP‑1) receptor agonists, as combined therapy may affect gastrointestinal tolerance.
• Anticoagulants, as volume changes may affect drug levels.